The goal of this study is gathering informations about patients' quality of life after combined modality treatment of rectal cancer to evaluate how combined modality treatment for rectal cancer affects patients' quality of life. The findings of this study may provide us important information that can be used in treatment decision and to develop programs to improve quality of life of patients with rectal cancer.
Over the last two decades, rectal cancer research has lead to better understanding of disease behaviour, resulting in more efficient treatments and higher prevalence of cancer survivors.Due to aggressive therapy, rectal cancer survivors can exhibit late sequelae of treatment, most common being impaired bowel, voiding, sexual malfunctioning and quality of life impairment. In order to determine the impact of rectal cancer and its treatment on patients' quality of life over time, this study will prospectively follow a cohort of patients at specified intervals evaluating their physical symptoms, physical and social functioning and overall quality of life.Medical and sociodemographic factors that might be predictive will be tested.
Study Type
OBSERVATIONAL
Enrollment
167
Quality of life assessment using questionnaires EORTC QLQ C30 and 38 at baseline, one year and two years after the surgery of rectal cancer, treated with preoperative capecitabine based radiochemotherapy
Institute of Oncology
Ljubljana, Slovenia, Slovenia
To prospectively evaluate the quality of life of patients one year after rectal cancer resection
Time frame: one year after the operation
To prospectively evaluate the quality of life of patients at baseline
consecutive patients treated winh capecitabine-based radiochemotherapy
Time frame: before treatment (at baseline)
To prospectively evaluate the quality of life of patients two years after rectal cancer resection
Time frame: two years after the operation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.